Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

PENICILLIN V (POTASSIUM)

All products: general benefit

Other products in the same Health Canada class (J01C) — coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

PEN V-K · DIN 00642215 · 300mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PEN V-K · DIN 00642215 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.7492 Health Canada: Marketed since 2014-09-05 · brand PEN-VK · ATC J01CE02 PHENOXYMETHYLPENICILLIN · form Tablet · route Oral · ingredients PENICILLIN V POTASSIUM 300 MG · company Robinson facility supply, inc. · schedule Prescription
Check this DIN again · Health Canada product record

PEN V-K: Formulary list price $0.1873/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1873 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6421 · Verify on the e-Formulary ↗ (DIN 00642215)

Source record
DIN 00642215: PEN V-K Raw flags: sec3=Y Item: 081216034; group id 29; item number 0061; lccId None; manufacturer id AAP Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1873; ministry $0.1873 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00642215 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6421
Interchangeable products
PVF-K 500 · DIN 00248843 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, AMPICILLIN, CLOXACILLIN 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFUROXIME AXETIL · General benefit (7), Listed, not a benefit (2) Indications CEFTIN (cefuroxime axetil for oral suspension) is indicated for the treatment of patients with mild to moderately severe infections caused by susceptible strains of the designated organisms in the following diseases: • Upper Respiratory Tract Infections: Pharyngitis and tonsillitis caused by Streptococcus pyogenes. PM: https://pdf.hres.ca/dpd_pm/00081954.PDF; date 2025-10-03; DIN 02212307; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications PEN-VK (Penicillin V Potassium (Phenoxymethylpenicillin Potassium)) is indicated for: • Mild to moderately severe infections caused by penicillin V sensitive microorganisms including streptococcal pharyngitis, staphylococcal infection without bacteremia and pneumococcal infections. Therapy should be guided by bacteriologic sensitivity tests and clinical response. Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with potassium phenoxymethyl penicillin during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of potassium phenoxymethyl penicillin: • Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. Note: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. • Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. • Staphylococcal infections sensitive to penicillin V: Mild infections of the… https://pdf.hres.ca/dpd_pm/00081311.PDF PM date: August 1, 2025 Source product: PEN-VK; DIN 00642215; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.